ASX Share rice
Tue 11 May 2021 - 06:10:pm (Sydney)

SPL Share Price

STARPHARMA HOLDINGS LIMITEDSPLPharmaceuticals, Biotechnology & Life Sciences

SPL Company Information

Name:

Starpharma Holdings Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

4-6 Southampton Crescent Abbotsford VIC Australia 3067

Phone:

61 3 8532 2700

CEO, MD & Exec. Director:

Dr. Jacinth K. Fairley B.Sc., B.V.Sc.(Hons), MBA, GAICD

CFO & Company Sec.:

Mr. Nigel J. Baade B.Com, Grad. Dip., CPA

Company Overview:

Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

SPL Share Price Information

Shares Issued:

406.08M

Market Capitalisation:

$698.45M

Revenue (TTM):

$1.52M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.04

Operating Margin (TTM):

$-13.44

Return On Assets (TTM):

$-0.21

Return On Equity (TTM):

$-0.36

Quarterly Revenue Growth (YOY):

-0.887

Gross Profit(TTM):

$5.67M

Diluted Earnings Per Share (TTM):

$-0.051

SPL CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-125,000

Change To Liabilities:

$-436,000

Total Cashflow From Investing Activities:

$-125,000

Net Borrowings:

$-584,000

Net Income:

$-14,678,000

Total Cash From Operating Activities:

$-10,776,000

Depreciation:

$0.91M

Change To Inventory:

$-95,000

Change To Account Receivables:

$31K

Capital Expenditures:

$125K

SPL Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-14,678,000

Net Income:

$-14,678,000

Gross Profit:

$6.23M

Operating Income:

$-14,678,000

Total Revenue:

$7.12M

Cost Of Revenue:

$890K

SPL Balance Sheet

Balance Sheet Date:

2020-06-30

Total Liabilities:

$7.75M

Total Stockholder Equity:

$31.33M

Other Current Liabilities:

$515K

Total Assets:

$39.08M

Common Stock:

$193.66M

Retained Earnings:

$-182,675,000

Other Liabilities:

$85K

Cash:

$25.98M

Total Current Liabilities:

$6.70M

Property - Plant & Equipment:

$2.40M

Net Tangible Assets:

$31.33M

Total Current Assets:

$36.68M

Net Receivables:

$6.09M

Short-Term Investments:

$2.40M

Inventory:

$494K

Accounts Payable:

$4.39M

Short-Term Investments:

$2.40

Non Current Liabilities Total:

$1.06M

SPL Share Price History

SPL News

07 May, 2021
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
23 Mar, 2021
Does the March share price for Starpharma Holdings Limited ( ASX:SPL ) reflect what it's really worth? Today, we will...
15 Feb, 2021
The big shareholder groups in Starpharma Holdings Limited ( ASX:SPL ) have power over the company. Institutions often...
12 Feb, 2021
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that is has signed a Research Agreement with MSD, the tradename of Merck & Co., Inc., Kenilworth NJ USA. Under the agreement, MSD will conduct a preclinical research evaluation of dendrimer based Antibody Drug Conjugates (ADCs) utilising Starpharma's proprietary DEP® technology.
08 Jan, 2021
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
03 Dec, 2020
Jackie Fairley has been the CEO of Starpharma Holdings Limited ( ASX:SPL ) since 2006, and this article will examine...
29 Oct, 2020
With the business potentially at an important milestone, we thought we'd take a closer look at Starpharma Holdings...
23 Sep, 2020
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Starpharma Holdings...
21 Sep, 2020
Individual and institutional investors as well as advisors are invited to log-on to LifeSciencesInvestorForum.com to view presentationsNEW YORK, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced that the presentations from the September 17th conference are now available for on-demand viewing at LifeSciencesInvestorForum.com. This virtual event showcased live company presentations and interactive discussions focused on the life sciences industry. The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download shareholder materials from the company’s “virtual trade booth”.REGISTER OR LOGIN AT:  https://bit.ly/3m5MTfYSeptember 17th Presenting Companies:Company NameTicker(s) Starpharma Holdings Ltd.OTCQX: SPHRY | ASX: SPL VolitionRx LimitedNYSE AMERICAN: VNRX KemPharm, Inc.OTCQB: KMPH Assure Holdings Corp.OTCQB: ARHH | TSX-V: IOM aTyr Pharma, Inc.Nasdaq: LIFE SWK Holdings, IncNasdaq: SWKH Cardiol Therapeutics Inc.OTCQX: CRTPF | TSX: CRDL XPhyto Therapeutics Corp.OTCQB: XPHYF | CSE: XPHY | FSE: 4XT Nuvo Pharmaceuticals Inc.OTCQX: NRIFF | TSX: NRI Salarius Pharmaceuticals, Inc.Nasdaq: SLRX Willow Biosciences Inc.OTCQB: CANSF | TSX: WLLW Orexo ABOTCQX: ORXOY | Nasdaq STO: ORX Caladrius Biosciences, Inc.Nasdaq: CLBS Kineta, IncPrivate Company Sixth Wave Innovations Inc.OTCQB: ATURF | CSE: SIXW | FSE: AHUH To facilitate investor relations scheduling and for more information about the program, please visit www.lifesciencesinvestorforum.com.About Life Sciences Investor Forum Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.CONTACT Life Sciences Investor Forum John M. Viglotti SVP Corporate Services, Investor Access (212) 220-2221 johnv@lifesciencesinvestorforum.com
15 Sep, 2020
Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.comMELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Starpharma (ASX: SPL, OTCQX: SPHRY), based in Melbourne, Australia, today announced that Dr Jackie Fairley, Chief Executive Officer, will present a pre-recorded presentation at LifeSciencesInvestorForum.com on September 17th.   DATE: Thursday, September 17th    TIME: 9:30 AM ET LINK: https://bit.ly/30GjErkIf attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.Learn more about the event at www.lifesciencesinvestorforum.com.About StarpharmaStarpharma Holdings Limited (ASX: SPL, OTCQX:SPHRY), located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses.  Starpharma has two core development programs: VivaGel® portfolio and DEP® drug delivery with the Company developing several products internally and others via commercial partnerships.VivaGel®: Starpharma’s women’s health product - VivaGel® BV is based on SPL7013, astodrimer sodium, a proprietary dendrimer. VivaGel® BV for bacterial vaginosis (BV), is available for sale under the brand names Betafem® BV Gel (UK), Betadine BV™ (Europe), Betadine™ BV Gel (Asia) and Fleurstat BVgel (Australia and New Zealand) and a new drug application has been submitted to the US FDA. Starpharma has licensed the sales and marketing of VivaGel® BV to ITF Pharma for the US; Mundipharma for Europe, Russia, CIS, Asia, the Middle East, Africa and Latin America; and to Aspen Pharmacare for Australia and New Zealand. Starpharma also has licence agreements to market the VivaGel® condom (an antiviral condom which includes VivaGel® in the lubricant) in several regions, including Australia, Europe, Canada, China and Japan (Okamoto). The VivaGel® condom has been launched in Japan under Okamoto’s 003 brand, and in Australia and Canada under the LifeStyles Dual Protect® brand. The VivaGel® condom is approved in Europe.DEP® \- Dendrimer Enhanced Product®: Starpharma’s DEP® drug delivery platform has demonstrated reproducible preclinical benefits across multiple internal and partnered DEP® programs, including improved efficacy, safety and survival. Starpharma has three internal DEP® products – DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan - in clinical development in patients with solid tumours. Starpharma’s partnered DEP® programs include a multiproduct DEP® licence with AstraZeneca, which involves the development and commercialisation of two novel oncology compounds, with potential to add more. In June 2019 Starpharma signed a Development and Option agreement with AstraZeneca for a DEP® version of one of AstraZeneca’s major marketed oncology medicines.About Life Sciences Investor Forum Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network. CONTACT: CONTACTS: Starpharma Holdings Limited Dr Jackie Fairley, Chief Executive Officer +61 3 8532 2704 investor.relations@starpharma.com  Life Sciences Investor Forum John M. Viglotti SVP Corporate Services, Investor Access (212) 220-2221 johnv@lifesciencesinvestorforum.com
14 Sep, 2020
Starpharma’s SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
Company executives will share corporate vision and answer audience questions at LifeSciencesInvestorForum.com NEW YORK, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Life Sciences Investor Forum today announced the agenda for its quarterly event for public and private companies, investors and industry professionals from around the world. This day-long virtual event will showcase live company presentations and interactive discussions focused on the life sciences industry.Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 9:15 AM ET on Thursday, September 17th with the first live webcast at 9:30 AM ET.REGISTER NOW AT: https://bit.ly/3m5MTfYIt is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend the live presentations or ask questions.Agenda and presenting companies:Eastern Time (ET)Company NameTicker(s) 9:30 AMStarpharma Holdings Ltd.OTCQX: SPHRY | ASX: SPL 10:00 AMVolitionRx LimitedNYSE AMERICAN: VNRX 10:30 AMKemPharm, Inc.OTCQB: KMPH 11:00 AMAssure Holdings Corp.OTCQB: ARHH | TSX-V: IOM 11:30 AMaTyr Pharma, Inc.Nasdaq: LIFE 12:00 PMSWK Holdings, IncNasdaq: SWKH 12:30 PMCardiol Therapeutics Inc.OTCQX: CRTPF | TSX: CRDL 1:00 PMXPhyto Therapeutics Corp.OTCQB: XPHYF | CSE: XPHY | FSE: 4XT 1:30 PMNuvo Pharmaceuticals Inc.OTCQX: NRIFF | TSX: NRI 2:00 PMSalarius Pharmaceuticals, Inc.Nasdaq: SLRX 2:30 PMWillow Biosciences Inc.OTCQB: CANSF | TSX: WLLW 3:00 PMOrexo ABOTCQX: ORXOY | Nasdaq STO: ORX 3:30 PMCaladrius Biosciences, Inc.Nasdaq: CLBS 4:00 PMKineta, IncPrivate Company 4:30 PMSixth Wave Innovations Inc.OTCQB: ATURF | CSE: SIXW | FSE: AHUH To facilitate investor relations scheduling and for more information about the program, please visit www.lifesciencesinvestorforum.com.About Life Sciences Investor Forum
 Life Sciences Investor Forum is the leading proprietary investor conference series that provides an interactive forum for Life Sciences companies to meet with and present directly to investors.A real-time solution for investor engagement, Life Sciences Investor Forum is powered by Intrado Digital Media and specifically designed for more efficient investor access. Replicating the look and feel of on-site investor conferences, Life Sciences Investor Forum combines leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network. CONTACT: CONTACT Life Sciences Investor Forum John M. Viglotti SVP Corporate Services, Investor Access (212) 220-2221 johnv@lifesciencesinvestorforum.com
01 Sep, 2020
Starpharma creates slow release soluble DEP® remdesivir nanoparticle
25 Aug, 2020
Starpharma SPL7013 nasal spray for COVID-19 – development update
28 Jul, 2020
A look at the shareholders of Starpharma Holdings Limited (ASX:SPL) can tell us which group is most powerful...
23 Jun, 2020
NEW YORK, June 23, 2020 -- Life Sciences Investor Forum today announced the agenda for its second quarterly event for public and private companies, investors and industry.
22 Jun, 2020
Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the June 18th conference are now available for on-demand viewing at VirtualInvestorConferences.com.
15 Jun, 2020
Virtual Investor Conferences today announced the agenda for the upcoming Global Virtual lnvestor Conference, the leading proprietary investor conference series. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 10:15 AM ET on Thursday, June 18th with the first live webcast at 10:30 AM ET